+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Companion Animal Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 5305873
  • Report
  • February 2022
  • Region: Global
  • 109 Pages
  • Mordor Intelligence


  • Biogenesis Bag
  • Bioveta AS
  • Boehringer Ingelheim GmbH
  • Brilliant Bio Pharma
  • Indian Immunologicals Ltd
  • Merck & Co. Inc.

The companion animal vaccine market was valued at approximately USD 2,923.0 million in 2021, and it is expected to register a CAGR of 6.08% over the forecast period.

The impact of the COVID-19 pandemic on the market is expected to be significant. Certain specific and precautionary guidelines were given to veterinary professionals to treat companion animals during the COVID-19 pandemic by the Centers for Disease Control and Prevention in July 2020. Additionally, many government authorities, such as the Centers for Disease Control and Prevention, recommended veterinary hospitals and clinics to prioritize urgent and emergency visits and procedures. This initiative by such national bodies may reduce the dependence on and usage of diagnostic equipment in veterinary healthcare management. Moreover, according to the OIE (World Organization for Animal Health), most veterinary laboratories are actively involved in testing COVID-19 in humans to overcome the shortage of healthcare facilities and COVID-19 testing laboratories globally. However, some hospitals and clinics are taking definite measures to avoid the transmission of the virus during this pandemic situation. For instance, Prestige Animal Hospitals has been taking precautionary measures in the treatment of animals. It also introduced a 'Drop Off Exams' program that allows the owner to drop off the animal for diagnosis or treatment. The results and treatment plans are then discussed through a phone call/e-mail. Hence, a slight short-term negative impact is witnessed on the companion animal vaccine market, primarily due to the reduced veterinary visits during the COVID-19 outbreak.

The growth of the companion animal vaccine market is primarily driven by the rising adoption of companion animals, such as dogs and cats, and the increasing cases of zoonotic diseases. At present, companion animals are among the major domesticated animals, and this category is dominated by dogs, cats, and horses. The market has been increasingly adopting drug crossovers from the human healthcare sector to the animal healthcare sector, especially dogs and cats.

According to the annual report of the European Pet Food Industry Association (FEDIAF), in 2020, dogs and cats were found to be the major pets adopted in Europe. Moreover, an estimate of 85 million European households owns at least one pet animal. The trend is further expected to increase during the forecast period.

In the past few years, considering the risk of transferring human diseases to animals and vice versa, the market observed increased demand for vaccines for companion animals.

Key Market Trends

The Live Attenuated Vaccines Segment is Expected to Hold a Major Share over the Forecast Period

Live attenuated vaccines contain a weakened version of the living microbe, making it ineffective to cause diseases. They produce a similar yet weakened reaction compared to natural infections. Effective cellular and antibody responses are established by the immune system with single or multiple doses of a vaccination, which aids in providing long-term immunity against infectious pathogens. The live attenuated vaccines are kept refrigerated to sustain their potency. Besides, if the vaccine needs to be shipped overseas or stored by healthcare workers, especially in developing countries that lack widespread refrigeration, a live vaccine may not be the best choice.

Mostly, vaccines licensed for oral or intranasal administration are attenuated. These vaccines must be stored and handled properly, and strict attention must be paid to temperature, even in the lyophilized (free-dried) state. After the reconstitution, the vaccine’s dose should be administered promptly (within one hour) or discarded.

Moreover, the development and launch of new vaccines and a robust pipeline are expected to boost the market growth. For instance, in December 2019, Merck Animal Health launched two new vaccines, namely the Nobivac EDGE DAPPV + L4, a combo vaccine to include parainfluenza protection, and the Nobivac EDGE DAPPV combo vaccine to include parainfluenza protection in dogs. Hence, these vaccines are expected to account for the largest market share during the forecast period.

The North American Companion Animal Vaccine Market is Anticipated to Grow Tremendously over the Forecast Period

The major factors driving the growth of the North American companion animal vaccine market include the increasing adoption of companion animals, the surging prevalence of diseases, such as zoonosis, and the availability of advanced veterinary healthcare infrastructure.

The growing pet population, along with an increase in spending on pet care, is also fueling the market growth. For instance, according to the 2019-2020 National Pet Owners Survey conducted by the American Pet Products Association (APPA), around 85 million families or 67% of US households owned a pet, up from 56% of US households in 1988. Additionally, during 2019-2020, around 63.4 million US households owned a dog. Furthermore, as per the National Institute of Statistics and Geography (INEGI) 2019, about 70% of Mexican households had at least one pet. Such high adoption in the region is driving the growth of the market.

Moreover, as per the American Pet Products Association Survey 2021-2022, it was estimated that in 2021 around USD 109.6 billion was spent on pets in the United States, up from USD 103.6 billion in 2020. Furthermore, the Centers for Disease Control and Prevention (CDC), the Department of the Interior (DOI), and the United States Department of Agriculture (USDA) released a 2019 report listing the zoonotic diseases of the greatest concern in the United States. This factor may boost the market growth, as it may increase the demand for vaccines to eradicate infectious diseases in companion animals.

To increase their market shares, market players are adopting various strategies, such as product launches, product developments, collaborations, mergers, acquisitions, and expansions. For instance, in October 2020, Elanco signed an agreement with Bayer’s Animal Health Business to acquire its Animal Health business in a transaction valued at USD 7.6 billion. Thus, the rising incidence rates of infectious diseases in companion animals, along with increasing product launches, may show significant market growth over the forecast period.

Competitive Landscape

The companion animal vaccine market is a moderately competitive market. In terms of market share, major players, such as Elanco Animal Health Incorporated, Boehringer Ingelheim GmbH, Merck & Co. Inc., Zoetis Inc., and Bioveta AS, among others, hold the largest market shares. Key players are evolving through various strategic alliances, such as acquisitions, collaborations, and new product launches, to expand the global product portfolios and secure their positions in the global market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown


  • Biogenesis Bag
  • Bioveta AS
  • Boehringer Ingelheim GmbH
  • Brilliant Bio Pharma
  • Indian Immunologicals Ltd
  • Merck & Co. Inc.

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of Companion Animals, such as Dogs and Cats
4.2.2 Increasing Cases of Zoonotic Diseases
4.3 Market Restraints
4.3.1 High Cost of Vaccine Development and Regulatory Concern
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Technology
5.1.1 Live Attenuated Vaccines
5.1.2 Inactivated Vaccines
5.1.3 Toxoid Vaccines
5.1.4 Recombinant Vaccines
5.1.5 Other Technologies
5.2 By Animal Type
5.2.1 Dogs
5.2.2 Cats
5.2.3 Other Animal Types
5.3 By Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1.1 Elanco Animal Health Incorporated
6.1.2 Boehringer Ingelheim GmbH
6.1.3 Brilliant Bio Pharma
6.1.4 Merck & Co. Inc.
6.1.5 Virbac
6.1.6 Zoetis Inc.
6.1.7 Indian Immunologicals Ltd
6.1.8 Bioveta AS
6.1.9 Vetoquinol SA
6.1.10 Merial (Sanofi)
6.1.11 Biogenesis Bag
6.1.12 Hygieia Biological Laboratories
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim GmbH
  • Brilliant Bio Pharma
  • Merck & Co. Inc.
  • Virbac
  • Zoetis Inc.
  • Indian Immunologicals Ltd
  • Bioveta AS
  • Vetoquinol SA
  • Merial (Sanofi)
  • Biogenesis Bag
  • Hygieia Biological Laboratories
Note: Product cover images may vary from those shown